Relationship between heat shock protein 60 (HSP6O) mRNA expression and resistance to platinum analogues in human ovarian and bladder carcinoma cell lines

Cancer Letters

Volumn 119, Issue 1, 1997, Pages 63-70

  Abu Hadid, M ^a   Wilkes, J D ^a   Elakawi, Z ^a   Pendyala, L ^a   Perez, R P ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Chaperonin; Cisplatin; Drug resistance; Heat shock proteins; Oxaliplatin

Indexed keywords

CISPLATIN; HEAT SHOCK PROTEIN 60; MESSENGER RNA; OXALIPLATIN; PLATINUM DERIVATIVE;

ARTICLE; BLADDER CARCINOMA; GENE CLUSTER; GENE NUMBER; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN FOLDING; PROTEIN TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHAPERONIN 60; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE DOSAGE; GENE EXPRESSION; HUMANS; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; URINARY BLADDER NEOPLASMS;

EID: 0030695416     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(97)00255-3     Document Type: Article

References (32)

1. R. Ozols, S. Rubin, A. Dembo, S. Robboy, Epithelial ovarian cancer, in: W. Hoskins, C. Perez, R. Young (Eds.), Principles and Practice of Gynecologic Oncology, J.B. Lippincott, Philadelphia, PA, 1992, pp. 731-781.
2. G. Sutton, F. Stehman, L. Einhorn, L. Roth, J. Blessing, C. Erlich, Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma, J. Clin. Oncol. 7 (1989) 223-229.
3. P. Andrews, S. Howell, Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance, Cancer Cells 2 (1990) 35-43.
4. R. Perez, T. Hamilton, R. Ozols, Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems, Pharmacol. Ther. 48 (1990) 19-27.
5. R. Perez, A. Godwin, T. Hamilton, R. Ozols, Ovarian cancer biology, Semin. Oncol. 18 (1991) 186-204.
6. L.R. Kelland, The molecular basis of cisplatin sensitivity/ resistance, Eur. J. Cancer 30A (1994) 725-727.
7. F.U. Hartl, R. Hlodan, T. Langer, Molecular chaperones in protein folding: the art of avoiding sticky situations, Trends Biochem. Sci. 19 (1994) 20-25.
8. E.A. Craig, B.D. Gambill, R.J. Nelson, Heat shock proteins: molecular chaperones of protein biogenesis, Microbiol. Rev. 57 (1993) 402-414.
9. W.J. Welch, The role of heat-shock proteins as molecular chaperones, Curr. Opin. Cell Biol. 3 (1991) 1033-1038.
10. R.J. Ellis, Molecular chaperones, Annu. Rev. Biochem. 60 (1991) 321-347.
11. J. Martin, A.L. Horwich, F.U. Hartl, Prevention of protein denaturation under heat stress by the chaperonin Hsp60, Science 258 (1992) 995-998.
12. R.E. Enns, D.K. Hom, F. Thiebaut, S.B. Howell, An amplified mitochondrial chaperonin gene causes resistance to cisplatin in human ovarian tumor cells (abstract), Proc. Am. Assoc. Cancer Res. 32 (1991) 353.
13. E. Kimura, R.E. Enns, J.E. Alcaraz, J. Arboleda, D.J. Slamon, S.B. Howell, Correlation of the survival of ovarian cancer patients with mRNA expression of the 60-kD heat shock protein HSP-60, J. Clin. Oncol. 11 (1993) 891-898.
14. B. Nakata, R. Barton, S.B. Howell, G. Los, Association between overexpression of hsp60 and cisplatin resistance in head and neck cancer cells (abstract), Proc. Am. Assoc. Cancer Res. 35 (1994) 466.
15. D.-W. Shen, I. Pastan, M. Gottesman, A 52 kD protein is overexpressed in cisplatin-resistant human liver carcinoma cells and in cisplatin-resistant mouse cells after DNA-mediated transformation (abstract), Proc. Am. Assoc. Cancer Res. 35 (1994) 441.
16. D.-W. Shen, N. Wang, I. Pastan, M.M. Gottesman, Identification of a protein overexpressed in cisplatin-resistant cell lines derived from human liver carcinoma and mouse Balb/ 3T3 cells as the heat shock protein HSP60 (abstract), Proc. Am. Assoc. Cancer Res. 36 (1995) 401.
17. J.L. Misset, Y. Kidani, J. Gastiaburu, C. Jasmin, F. Levi, N. Boughattas, G. Lemaigre, J.P. Caussanel, B. Triana, E. Goldschmidt, M. Musset, R.Y. Mauvernay, G. Mathe, Oxaliplatin (1-OHP): experimental and clinical studies, in: S.B. Howell (Ed.), Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, Plenum Press, New York, 1991, pp. 369-375.
18. E. Cvitkovic, M. Fereres, P. Soulie, J.F. Llory, O. Rixe, C. Garrino, M. Marty, J.L. Misset, High activity in pretreated germ cell tumors (GCT) of combined oxaliplatin (1-OHP) cisplatin (CP) based salvage regimen (abstract), Proc. Am. Assoc. Cancer Res. 35 (1994) 233.
19. J.L. Misset, P. Soulie, M. Fereres, J.F. Llory, E. Raymond, M. Musset, P. Chollet, C. Jasmin, C. Garrino, E. Cvitkovic, High efficacy of combined oxaliplatin (1-OHP) cisplatin (CP) as salvage treatment in pretreated ovarian cancer (OC) (abstract), Proc. Am. Assoc. Cancer Res. 35 (1994) 234.
20. B.C. Behrens, T.C. Hamilton, H. Masuda, Characterization of a cis-diamminedichloroplatinum (II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues, Cancer Res. 47 (1987) 414-418.
21. A.K. Godwin, A. Meister, P.J. O'Dwyer, High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis, Proc. Natl. Acad. Sci. USA 89 (1992) 3070-3074.
22. H. Masuda, R.F. Ozols, G.-M. Lai, A. Fojo, M. Rothenberg, T.C. Hamilton, Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines, Cancer Res. 48 (1988) 5713-5716.
23. S.W. Johnson, R.P. Perez, A.K. Godwin, Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines, Biochem. Pharmacol. 47 (1994) 689-697.
24. J. Glavy, L. Pendyala, P.J. Creaven, R. Perez, J. Zdanowicz, Z. Elakawi, Isolation and preliminary characterization of oxaliplatin resistant A2780 ovarian carcinoma sublines (abstract), Proc. Am. Assoc. Cancer Res. 35 (1994) 434.
25. P.J. Russell, D. Raghavan, P. Gregory, J. Phillips, E.J. Wills, M. Jelbart, J. Wass, R.A. Zbroja, P.C. Vincent, Bladder cancer xenografts: a model of tumor cell heterogeneity, Cancer Res. 46 (1986) 2035-2040.
26. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J. Warren, H. Bokesch, S. Kenney, M. Boyd, New colorimetric cytotoxicity assay for anticancer drug screening, J. Natl. Cancer Inst. 82 (1990) 1107-1112.
27. R. Perez, A. Godwin, L. Handel, T. Hamilton, A comparison of clonogenic, microtetrazolium (MTT), and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines, Eur. J. Cancer 29A (1993) 395-399.
28. P. Chomczynski, A reagent for the single-step simultaneous isolation of RNA, DNA, and proteins from cell and tissue samples, Biotechniques 15 (1993) 532-536.
29. W. Warren, T. Wheat, P. Knudsen, Rapid analysis and quantitation of PCR products by high-performance liquid chromatography, Biotechniques 11 (1991) 250-255.
30. Z. El-akawi, M. Abu-hadid, R. Perez, J. Glavy, J. Zdanowicz, P.J. Creaven, L. Pendyala, Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells, Cancer Lett. 105 (1996) 5-14.
31. T.J. Venner, B. Singh, R.S. Gupta, Nucleotide sequences and novel structural features of human and Chinese hamster hsp60 (chaperonin) gene families, DNA Cell Biol. 9 (1990) 545-552.
32. E.H. Richards, E. Hickey, L. Weber, J.R.W. Masters, Effect of overexpression of the small heat shock protein HSP27 on the heat and drug sensitivities of human testis tumor cells, Cancer Res. 56 (1996) 2446-2451.